Old Web
English
Sign In
Acemap
>
authorDetail
>
Mayumi Kimura
Mayumi Kimura
Mitsubishi Tanabe Pharma
Internal medicine
Diabetes mellitus
Type 2 Diabetes Mellitus
Medicine
Canagliflozin
3
Papers
59
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Discovery of 2-[(E)-2-(7-fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin- 1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine hydrochloride as a highly selective PDE10A inhibitor
2018
Chemical & Pharmaceutical Bulletin
Yoichi Kadoh
Haruko Miyoshi
Takehiko Matsumura
Yoshihito Tanaka
Mitsuya Hongu
Mayumi Kimura
Kei Takedomi
Kenji Omori
Jun Kotera
Takashi Sasaki
Tamaki Kobayashi
Hiroyuki Taniguchi
Yumi Watanabe
Koki Kojima
Toshiaki Sakamoto
Toshiyuki Himiyama
Eiji Kawanishi
Show All
Source
Cite
Save
Citations (6)
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
2018
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Yuya Seko
Taichiro Nishikawa
Atsushi Umemura
Kanji Yamaguchi
Michihisa Moriguchi
Kohichiroh Yasui
Mayumi Kimura
Hiroaki Iijima
Toshio Hashimoto
Yoshio Sumida
Takeshi Okanoue
Yoshito Itoh
Show All
Source
Cite
Save
Citations (43)
Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus
2018
Expert Opinion on Pharmacotherapy
Takashi Kadowaki
Masakazu Haneda
Hiroshi Ito
Makoto Ueno
Miyuki Matsukawa
Tomoko Yamakura
Kazuyo Sasaki
Mayumi Kimura
Hiroaki Iijima
Show All
Source
Cite
Save
Citations (10)
1